NEW YORK (Reuters Health)—The investigational drug romosozumab led to gains in hip bone mineral density (BMD) that were not seen with teriparatide in older women with osteoporosis transitioning from bisphosphonate therapy in the STRUCTURE study. Amgen’s romosozumab is a monoclonal antibody that inhibits sclerosin, a negative regulator of bone formation. In addition to stimulating bone…
Search results for: hospital
2017 Update of Treat-to-Target Recommendations for Axial & Peripheral SpA & PsA
An international task force has updated recommendations for axial and peripheral spondyloarthritis, and psoriatic arthritis, which include treat-to-target recommendations…
Oversupply of Opioids after Surgery Helps Fuel Opioid Epidemic
(Reuters Health)—More than two-thirds of surgery patients in a recent study had prescription opioids left over after they recovered from their operations, and the vast majority failed to safely store or dispose of the often misused and abused pills, researchers say. “Unused opioids that have been prescribed for pain after surgery serve as an important…
Refocus Your Practice with Invigorating Sessions in San Diego
The landscape of practice management and coding methodologies continues to be challenging in the current healthcare environment, and rheumatology practices must maintain focus on managing an effective and efficient practice. Join us at the 2017 ACR/ARHP Annual Meeting, Nov. 3–8 in San Diego, and gain knowledge and understanding of best practices in an ever-changing environment…
Online Risk Calculator for Knee OA Influences Patient Risk Perception
A new tool for assessing the risk of developing knee osteoarthritis (OA) may be useful for knee OA education. A recent study found the online risk calculator, OA Risk C, was effective in helping patients better understand their personal risk of developing the disease. It may also motivate some patients to embrace exercise-related behavior changes…
Abatacept Approved for Adult PsA
The FDA has approved abatacept to treat adults with active psoriatic arthritis. In clinical trials, the treatment has proved effective in both intravenous and subcutaneous forms…
What Rheumatologists Are Paid
A 2017 survey showed that rheumatologists’ pay has plateaued. And according to Anne Bass, MD, many cognitive fields, such as pediatrics and endocrinology, remain underpaid due to the current reimbursement structure…
Progress Made During HOD Annual Meeting
The AMA House of Delegates (HOD) met in Chicago for its annual meeting June 9–14. More than 530 HOD members were present, with several hundred AMA and association staff and guests. As I am sure you have noted from past issues of ACR@Work, the ACR is in its five-year membership review. The ACR must be…
Anti-CarP May Play Special Role in RA-Associated Mortality
Researchers may have established a relationship between a new RA autoantibody, anti-carbamylated protein (anti-CarP) antibodies, and increased mortality risk. The recent study showed that anti-CarP was the only autoantibody associated with mortality, specifically respiratory system cause of death…
Rheumatology Drug Updates: Uncertain Future for Romosozumab, Plus FDA Approves Tocilizumab for GCA
Romosozumab’s Future Is Uncertain Romosozumab, which has the possible U.S. brand name Evenity, is awaiting approval from the FDA.1 The treatment is an investigational, injectable biologic for treating osteoporosis. It increases bone formation and bone density, reducing a patient’s risk of fractures. The manufacturer no longer expects the FDA to approve the drug this year…
- « Previous Page
- 1
- …
- 184
- 185
- 186
- 187
- 188
- …
- 330
- Next Page »